secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001104659-24-044325
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics reports FY2023 operating loss of $19.4M; cash $2.8M at year-end
--------------------------------------------------------------------------------

- Cash $2.8M as of Dec 31, 2023; net $6.2M raised in Jan 2024; funding expected into late Q3/Q4 2024.
- R&D expenses $12.3M (up from $10.2M in 2022); G&A $7.2M (down from $8.4M); operating loss $19.4M.
- CEO Michael Dudley resigned; CFO Tom Fitzgerald named interim CEO; Philippe Calais appointed Executive Chairman.
- Phase 0 trial of TTX-MC138 completed; preliminary results suggest delivery to metastatic lesions in breast cancer patient.
- Phase 1 trial of TTX-MC138 planned mid-2024 subject to FDA authorization and IRB approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/0001104659-24-044325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924044325/tm2411028d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-044325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer